The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS)
The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Doron Gothelf, MD
- Phone Number: 972-03-5302663
- Email: gothelf@post.tau.ac.il
Study Locations
-
-
-
Petah Tikva, Israel, 49202
- Recruiting
- Schneider Children's Mediac Center of Israel
-
Contact:
- Doron Gothelf, MD
- Phone Number: 972-03-5302663
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- chromosomal deletion proven by FISH examination
Exclusion Criteria:
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Measure that are used: psychological measures, molecular tests, responsiveness to medical treatments
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Aortic Valve Disease
- Neurologic Manifestations
- Endocrine System Diseases
- Musculoskeletal Diseases
- Nervous System Diseases
- Cardiovascular Diseases
- Heart Diseases
- Genetic Diseases, Inborn
- Neurobehavioral Manifestations
- Heart Valve Diseases
- Lymphatic Diseases
- Craniofacial Abnormalities
- Musculoskeletal Abnormalities
- Congenital Abnormalities
- Parathyroid Diseases
- Cardiovascular Abnormalities
- Heart Defects, Congenital
- Abnormalities, Multiple
- Heredodegenerative Disorders, Nervous System
- Intellectual Disability
- Genetic Diseases, X-Linked
- Aortic Valve Stenosis
- Sex Chromosome Disorders
- Chromosome Disorders
- Aortic Stenosis, Supravalvular
- Lymphatic Abnormalities
- Hypoparathyroidism
- 22q11 Deletion Syndrome
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Hemic and Lymphatic Diseases
- X-Linked Intellectual Disability
- Fragile X Syndrome
- Williams Syndrome
- DiGeorge Syndrome
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Carboxylic Acids
- Amines
- Piperidines
- Pyrimidines
- Pyrimidinones
- Acids, Carbocyclic
- Propylamines
- Phenylacetates
- Methylphenidate
- Fluoxetine
- Risperidone
Other Study ID Numbers
Other Study ID Numbers
- SCMCI082455CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.